trichosanthin |
|
Vaxjo ID |
263 |
|
Vaccine Adjuvant Name |
trichosanthin |
|
Alternative Names |
Tian Hua Fen (traditional name in Chinese medicine) |
|
Adjuvant VO ID |
VO_0005750
|
|
Description |
TCS is a type I ribosome-inactivating protein derived from Trichosanthes kirilowii. It has known anticancer and immunostimulatory activity and was repurposed as an adjuvant in a genetically engineered “all-in-one” cancer vaccine with cell-penetrating and antigenic peptide sequences. TCS is licensed in China as a gynecological drug (not as a vaccine). |
|
Stage of Development |
Research |
|
Host Species for Testing |
Human |
|
Second Host Species for Testing |
Mouse |
|
Components |
a novel cancer immunostimulant, trichosanthin (TCS), that is a clinically used protein drug in China, and developed a well-adaptable protein-engineering method for making recombinant protein vaccines by fusion of an antigenic peptide |
|
Structure |
Single-chain protein Modified to include cell-penetrating peptide (LMWP) and tumor antigens (e.g., legumain, TRP2) |
|
Appearance |
Likely white or off-white powder after lyophilization. |
|
Storage |
Stored as purified recombinant protein in PBS. Endotoxin-free and suitable for in vivo use. |
|
Preparation |
Expressed in E. coli Purified using IMPACT system, FPLC, and endotoxin removal Recombinant fusion proteins include TCS + tumor antigen + LMWP |
|
Dosage |
Topical (microneedle-assisted): 50 μg protein per dose Subcutaneous: 5 μg per dose (1/10 of topical) |
|
Function |
We discovered a novel cancer immunostimulant, trichosanthin (TCS), that is a clinically used protein drug in China, and developed a well-adaptable protein-engineering method for making recombinant protein vaccines by fusion of an antigenic peptide, TCS, and a cell-penetrating peptide (CPP), termed an all-in-one vaccine, for transcutaneous cancer immunization. |
|
Safety |
Safe in mice |
| References |
Wu et al., 2021: Wu A, Chen Y, Wang H, Chang Y, Zhang M, Zhao P, Tang Y, Xu Q, Zhu Z, Cao Y, Huang Y. Genetically-engineered "all-in-one" vaccine platform for cancer immunotherapy. Acta pharmaceutica Sinica. B. 2021; 11(11); 3622-3635. [PubMed: 34900541].
|
